echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Shanton has screened the first subjects in the Phase II.b study of SAP-001 refractory/tophi gout

    Shanton has screened the first subjects in the Phase II.b study of SAP-001 refractory/tophi gout

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanton Pharma, a clinical-stage biotechnology company that has developed a breakthrough treatment for patients with refractory/tophi gout, announced the launch of the RID GOUT study, a Phase IIb study
    of Shanton's investigational drug, SAP-001, on January 9.

    "Gout is a chronic accumulation disease with serious complications associated with the accumulation of uric acid in joints and other tissues and organs
    .
    There is a clear unmet medical need, and patients have few options for treating chronic refractory/tophi gout," said Dr.
    Huang Zhenhua, Chairman of Shanton Pharma, "Shanton's experienced team and the good safety and efficacy of SAP-001 are well positioned to provide better solutions for this group of patients with unmet medical needs, thereby achieving effective tophi lysis and long-term normalization of blood uric acid levels.
    "

    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.